Acelot has dosed the first healthy volunteer in a Phase 1a clinical trial testing ACE-2223, its investigational oral treatment candidate designed to target aggregated TDP-43 in people with amyotrophic ...

Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced the initiation of the Phase Ia clinical trial of ACE-2223 ...

Jordan Tannahill Always Orders Fish Where He Shouldn’t “I don’t know why I’m inclined to order salmon at a hospital, but I do.” ...

It isn't a secret that abortion rights are a hot-button subject, even in blue states such as California. AB 2223 seems to protect reproductive rights in the eyes of some, while others believe the bill ...

Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS) ACE-2223 is the ...